Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Fortress Biotech (FBIO) Operating Margin: 2013-2025

Historic Operating Margin for Fortress Biotech (FBIO) over the last 13 years, with Sep 2025 value amounting to -38.63%.

  • Fortress Biotech's Operating Margin rose 11240.00% to -38.63% in Q3 2025 from the same period last year, while for Sep 2025 it was -143.55%, marking a year-over-year increase of 2615.00%. This contributed to the annual value of -191.38% for FY2024, which is 2295.00% down from last year.
  • According to the latest figures from Q3 2025, Fortress Biotech's Operating Margin is -38.63%, which was up 82.62% from -222.22% recorded in Q2 2025.
  • Fortress Biotech's Operating Margin's 5-year high stood at -38.63% during Q3 2025, with a 5-year trough of -473.63% in Q1 2023.
  • For the 3-year period, Fortress Biotech's Operating Margin averaged around -191.48%, with its median value being -169.85% (2025).
  • The largest annual percentage gain for Fortress Biotech's Operating Margin in the last 5 years was 26,737bps (2023), contrasted with its biggest fall of 27,605bps (2023).
  • Quarterly analysis of 5 years shows Fortress Biotech's Operating Margin stood at -339.25% in 2021, then skyrocketed by 620bps to -333.05% in 2022, then soared by 23,472bps to -98.34% in 2023, then plummeted by 5,930bps to -157.64% in 2024, then surged by 11,240bps to -38.63% in 2025.
  • Its Operating Margin stands at -38.63% for Q3 2025, versus -222.22% for Q2 2025 and -169.85% for Q1 2025.